Compare Levi Strauss & Co. (LEVI) vs Repligen Corporation Common Stock (RGEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Levi Strauss & Co. vs Repligen Corporation Common Stock — how do they compare? Levi Strauss & Co. trades at $19.56 (market cap $7.47B), while Repligen Corporation Common Stock trades at $178.15 (market cap $11.14B). The key difference: Repligen Corporation Common Stock is the larger of the two by market cap, and Levi Strauss & Co. pays a 3.29% dividend while Repligen Corporation Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Levi Strauss & Co. for 71 Days and Repligen Corporation Common Stock for 0 Days on average.
| LEVI | RGEN | |
|---|---|---|
Market Cap | $7.47B | $11.14B |
Volume | 6,427,839 | 1,259,263 |
Sector | Consumer Cyclical | Health |
52-Week High | $25.53 | $194.57 |
52-Week Low | $17.92 | $102.87 |
Typical Hold Time | 71 Days | 0 Days |
Enterprise Value | $9.02B | $11.02B |
Dividend Yield | 3.29% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Levi Strauss (LEVI) trades at $19.57, up 1.72% with strong fundamentals including a 12.82 P/E ratio and 25.76% ROE. The stock shows bearish technical signals but has consistently beaten earnings expectations for four consecutive quarters. Recent news highlights the company's successful '90s fashion revival and appointment of a new CFO, while analyst consensus remains strongly bullish with a $29 price target representing 48% upside potential.
The investment case balances attractive valuation against technical weakness. Strong profitability metrics and consistent earnings beats support upside, but bearish technical indicators and execution risks in the competitive apparel sector warrant caution. The 78.95% buy rating from analysts suggests significant institutional confidence in Levi's growth trajectory despite near-term market sentiment concerns.
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Levi Strauss & Co.
Levi Strauss & Co is involved in designing, marketing, and selling products that include jeans, casual and dresses pants, tops, shorts, skirts, jackets, footwear, and related accessories directly or through third parties and licensees for men, women, and children under Levi's, Dockers, Signature by Levi Strauss & Co. and Denizen brands. The company manages its business according to three regional segments: the Americas, which is the key revenue driver
Read more on LEVI →About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →
